Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer

Part of paid clinical trials in Buffalo, New York.

Sponsor
Roswell Park Cancer Institute
Study ID
NCT00470535
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • erlotinib hydrochloride — DRUG
    Oral
  • immunohistochemistry staining method — OTHER
    Correlative Study
  • laboratory biomarker analysis — OTHER
    Correlative Study

Study Details

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with stage III or stage IV pancreatic cancer.

Key Dates

First listed
May 7, 2007
Start date
Jan 31, 2007
Status verified
Jan 2017
Primary completion
Jan 31, 2009
Completion
Sep 30, 2010

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1 - Oral Erlotinib hydrochloride
    Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity

Primary Outcome Measure

Progression-free Survival [ Time Frame: Every cycle for up to 52 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Roswell Park Cancer InstituteBuffaloNew York14263-0001-

Find similar trials in Buffalo, NY

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Roswell Park Cancer Institute· Buffalo, NY

Related Studies